Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.mehy.2020.110246

http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.110246
suck pdf from google scholar
33254551!7470720!33254551
unlimited free pdf from europmc33254551    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33254551      Med+Hypotheses 2020 ; 144 (ä): 110246
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Can roflumilast become steroid-sparing alternative in the treatment of COVID-19? #MMPMID33254551
  • Shah CA
  • Med Hypotheses 2020[Nov]; 144 (ä): 110246 PMID33254551show ga
  • According to WHO the worst of the COVID-19 pandemic is yet to come. Despite of the exceptional measures being undertaken by regulatory agencies to expedite vaccine development, we may be several months if not years away from an effective vaccine. In such unprecedented times, the only resort nations have at their disposal is to identify and repurpose existing drugs against COVID-19 based on their known clinical or pharmacological profile which can provide direct or corroborative evidence of favorable benefit: risk in the management of COVID-19. Immune-mediated inflammation remains the hallmark of severe complications related to COVID-19 and while corticosteroids have shown preliminary evidence of benefit, they can act like a double-edged sword for majority of COVID-19 patients. Therefore, there is a need to identify 'non-steroid' potent and safe anti-inflammatory agents for use in therapeutic armamentarium against COVID-19. This article makes a case for one such existing drug, roflumilast, that can emerge as a steroid-sparing alternative against COVID-19.
  • |*COVID-19 Drug Treatment[MESH]
  • |Adrenal Cortex Hormones/therapeutic use[MESH]
  • |Aminopyridines/*therapeutic use[MESH]
  • |Animals[MESH]
  • |Anti-Inflammatory Agents/therapeutic use[MESH]
  • |Benzamides/*therapeutic use[MESH]
  • |Cyclopropanes/therapeutic use[MESH]
  • |Cytokine Release Syndrome/virology[MESH]
  • |Cytokines/metabolism[MESH]
  • |Humans[MESH]
  • |Immune System[MESH]
  • |Immunity, Innate[MESH]
  • |Inflammation[MESH]
  • |Models, Theoretical[MESH]
  • |Phosphodiesterase 4 Inhibitors/therapeutic use[MESH]
  • |Risk[MESH]
  • |Steroids/*therapeutic use[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box